PMC:7212965 / 1615-1783 JSONTXT

{"project":"LitCovid-PD-FMA-UBERON","denotations":[{"id":"T5","span":{"begin":81,"end":86},"obj":"Body_part"}],"attributes":[{"id":"A5","pred":"fma_id","subj":"T5","obj":"http://purl.org/sig/ont/fma/fma7197"}],"text":"s reported on hospitalized patients. The pooled prevalence estimates of elevated liver abnormalities were as follows: aspartate transaminase 15.0% (95% CI, 13.6%–16.5%)"}

{"project":"LitCovid-PD-UBERON","denotations":[{"id":"T5","span":{"begin":81,"end":86},"obj":"Body_part"}],"attributes":[{"id":"A5","pred":"uberon_id","subj":"T5","obj":"http://purl.obolibrary.org/obo/UBERON_0002107"}],"text":"s reported on hospitalized patients. The pooled prevalence estimates of elevated liver abnormalities were as follows: aspartate transaminase 15.0% (95% CI, 13.6%–16.5%)"}

{"project":"LitCovid-PD-CLO","denotations":[{"id":"T15","span":{"begin":81,"end":86},"obj":"http://purl.obolibrary.org/obo/UBERON_0002107"},{"id":"T16","span":{"begin":81,"end":86},"obj":"http://www.ebi.ac.uk/efo/EFO_0000887"}],"text":"s reported on hospitalized patients. The pooled prevalence estimates of elevated liver abnormalities were as follows: aspartate transaminase 15.0% (95% CI, 13.6%–16.5%)"}

{"project":"LitCovid-PD-CHEBI","denotations":[{"id":"T4","span":{"begin":118,"end":127},"obj":"Chemical"}],"attributes":[{"id":"A4","pred":"chebi_id","subj":"T4","obj":"http://purl.obolibrary.org/obo/CHEBI_132943"},{"id":"A5","pred":"chebi_id","subj":"T4","obj":"http://purl.obolibrary.org/obo/CHEBI_29995"},{"id":"A6","pred":"chebi_id","subj":"T4","obj":"http://purl.obolibrary.org/obo/CHEBI_72314"}],"text":"s reported on hospitalized patients. The pooled prevalence estimates of elevated liver abnormalities were as follows: aspartate transaminase 15.0% (95% CI, 13.6%–16.5%)"}

{"project":"LitCovid-PD-HP","denotations":[{"id":"T10","span":{"begin":81,"end":100},"obj":"Phenotype"}],"attributes":[{"id":"A10","pred":"hp_id","subj":"T10","obj":"http://purl.obolibrary.org/obo/HP_0001392"}],"text":"s reported on hospitalized patients. The pooled prevalence estimates of elevated liver abnormalities were as follows: aspartate transaminase 15.0% (95% CI, 13.6%–16.5%)"}

{"project":"LitCovid-PubTator","denotations":[{"id":"56","span":{"begin":27,"end":35},"obj":"Species"},{"id":"61","span":{"begin":72,"end":100},"obj":"Disease"}],"attributes":[{"id":"A56","pred":"tao:has_database_id","subj":"56","obj":"Tax:9606"},{"id":"A61","pred":"tao:has_database_id","subj":"61","obj":"MESH:D006973"}],"namespaces":[{"prefix":"Tax","uri":"https://www.ncbi.nlm.nih.gov/taxonomy/"},{"prefix":"MESH","uri":"https://id.nlm.nih.gov/mesh/"},{"prefix":"Gene","uri":"https://www.ncbi.nlm.nih.gov/gene/"},{"prefix":"CVCL","uri":"https://web.expasy.org/cellosaurus/CVCL_"}],"text":"s reported on hospitalized patients. The pooled prevalence estimates of elevated liver abnormalities were as follows: aspartate transaminase 15.0% (95% CI, 13.6%–16.5%)"}